•
Dec 30, 2024

Lyell Immunopharma Q4 2024 Earnings Report

Expected Revenue:$0
Expected EPS:-$0.13
+38.1% YoY
Total Revenue
$11K
Previous year: $13K
-15.4%
Gross Profit
-$5.02M
Previous year: -$5.04M
-0.6%
Cash and Equivalents
$371M
Previous year: $563M
-34.2%
Free Cash Flow
-$47.3M
Previous year: -$40.7M
+16.3%
Total Assets
$491M
Previous year: $750M
-34.6%

Lyell Immunopharma

Lyell Immunopharma